<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894398</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-04318</org_study_id>
    <nct_id>NCT02894398</nct_id>
  </id_info>
  <brief_title>Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant</brief_title>
  <acronym>INGE-B</acronym>
  <official_title>Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and quality of life in women with
      advanced breast cancer (locally advance inoperable or metastatic adenocarcinoma of the
      breast), HR+ / HER2-, who are treated with an aromatase inhibitor or fulvestrant as baseline
      therapy in combination with palbociclib (Ibrance)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, multi-center, single arm, non-comparative phase II study
      in women with HR+/HER2- advanced breast cancer receiving palbociclib in addition to an
      aromatase inhibitor or fulvestrant. The study will take place in Germany (85 study centers).

      In total, 360 patients will be enrolled in this study. 6 treatment groups are planned. The
      study seeks to recruit 60 (58-62) patients per recruitment group. For first-line treatment
      with palbociclib - and letrozole (Enrollment Group 1), anastrozole (Enrollment Group 2),
      exemestane (Enrollment Group 3) or fulvestrant (Enrollment Group 4) and 60 (58-62) patients
      for second- or later-line treatment with palbociclib -and letrozole (Enrollment Group 5) or
      fulvestrant (Enrollment Group 6). Recruitment will be centrally monitored to allow closure of
      a respective group as soon as 60 (58-62) patients have been enrolled.

      Treatment will be continued until disease progression, intolerable toxicity, death or any
      other reason. In case a combination partner is discontinued, palbociclib has to be
      discontinued. In case treatment with palbociclib is stopped, combination partner can be
      continued according to investigator's discretion. Irrespectively of the combination partner,
      the discontinuation of palbociclib is defined as end of treatment (EOT) in this study. After
      EOT the patient enters the follow-up period.

      Primary end point is clinical benefit rate 24 weeks after the first study treatment of the
      patient.

      A study independent, decentral, &quot;virtual&quot; biobank will be established. All patients will be
      asked to give consent for their tumor samples to be used for future investigational research.
      Study sites will inform the local pathologists about the patient's consent and ask for the
      tissue sample to be reserved for future analyses. The site is requested to collect contact
      details of the pathologist storing the tumor sample, the sample's identification number(s),
      and to document these in the eCRF.

      The decision to perform subsequent investigational research studies on collected samples will
      be based on outcome data from this study or from new scientific findings related to the drug
      class or disease, as well as reagent and assay availability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>24 weeks after first administration of Palbociclib in combination with AI / fulvestrant</time_frame>
    <description>CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events as assessed by CTCAE V4.0</measure>
    <time_frame>From Date of Signed informed consent until PD, assessed up to 60 months.</time_frame>
    <description>Adverse Events as characterized by type, frequency, severity (as graded by National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v.4.03), and seriousness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>48 weeks after first administration of Palbociclib in combination with AI / fulvestrant</time_frame>
    <description>CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival rate</measure>
    <time_frame>At 48 weeks (all patients) and 2 years (first-line patients only) after first administration of Palbociclib in combination with AI / fulvestrant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival rate</measure>
    <time_frame>At 48 weeks after first administration of Palbociclib in combination with AI / fulvestrant and yearly until EOS, assessed up to 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on treatment</measure>
    <time_frame>From day of first treatment until permanent discontinuation (EOT), assessed up to 60 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage</measure>
    <time_frame>From day of first treatment until EOT, assessed up to 60 months.</time_frame>
    <description>starting dose (mg)
adjusted doses (mg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adminstration schedule</measure>
    <time_frame>From day of first treatment until EOT, assessed up to 60 months.</time_frame>
    <description>- dates of administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.</time_frame>
    <description>Health-related QoL will be assessed with the FACT-B (Functional Assessment of Cancer Therapy-Breast) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related fatigue</measure>
    <time_frame>From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.</time_frame>
    <description>Fatigue will be assessed with the BFI (Brief Fatigue Inventory) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related anxiety and depression</measure>
    <time_frame>From date of signed informed consent until disease progression or start of next anti-cancer therapy: every 12 weeks, assessed up to 60 months.</time_frame>
    <description>Depression and anxiety will be assessed with the HADS-D (Hospital Anxiety and Depression Scale) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's assessment of patient's overall health status and change in health status compared to previous visit</measure>
    <time_frame>From Screening until disease progression or start of next anti-cancer therapy, assessed up to 60 months.</time_frame>
    <description>Assessed by 2 items at each cycle/at scheduled patient visit</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hormone Receptor Positive Tumor</condition>
  <condition>Human Epidermal Growth Factor 2 Negative Carcinoma of Breast</condition>
  <arm_group>
    <arm_group_label>Palbociclib+AI or Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole as first-line or later line, Anastrozole as first-line, Exemestane as first-line, Fulvestrant as first-line or later line after prior endocrine therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.
Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons</description>
    <arm_group_label>Palbociclib+AI or Fulvestrant</arm_group_label>
    <other_name>Ibrance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake</description>
    <arm_group_label>Palbociclib+AI or Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake</description>
    <arm_group_label>Palbociclib+AI or Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake</description>
    <arm_group_label>Palbociclib+AI or Fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection</description>
    <arm_group_label>Palbociclib+AI or Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Personally signed written informed consent prior to beginning protocol specific
             procedures, including expected cooperation of the patient for the treatment and
             follow-up, must be obtained and documented according to the local regulatory
             requirements

          2. Women with proven diagnosis of advanced, defined as locally advanced inoperable or
             metastatic, adenocarcinoma of the breast

          3. Hormone-receptor-positive (HR+) disease, defined as estrogen-receptor-positive (ER+)
             and/or progesterone-receptor-positive (PgR+)

          4. Human epidermal growth factor receptor 2-negative (HER2-) disease (HER2 neg/+ or
             HER2++ with CISH/FISH neg.)

          5. Pre-/perimenopausal women receiving concomitant therapy with an luteinizing
             hormone-releasing hormone (LHRH) agonist / ovarian ablation or postmenopausal status

          6. Age ≥18 years

          7. Measurable disease as per Response Evaluation Criteria in Solid Tumors [RECIST] or
             bone-only disease

          8. Patients scheduled for palliative treatment with an combination partner for first- or
             later-line

          9. Eastern Cooperative Oncology Group (ECOG) performance status 0-2

         10. Adequate organ and marrow function

         11. Resolution of all acute toxic effects of prior therapy, including radiotherapy Grade
             &lt;1 (except toxicities not considered a safety risk for the patient) and recovery from
             surgical procedures

         12. Fluent in spoken and written German

        Exclusion Criteria:

          1. Prior treatment with any CDK4/6 inhibitor

          2. Prior adjuvant therapy with the respective endocrine combination partner if last
             intake &lt;12 months prior to entering the study

          3. Prior palliative therapy with the respective endocrine combination partner

          4. More than one prior palliative chemotherapy

          5. 5. Known hypersensitivity to letrozole, anastrozole, exemestane, fulvestrant or any of
             their excipients

          6. Current use of food or drugs known to be potent inhibitors or inducers of CYP3A4
             (refer to Appendix 15.4)

          7. Current use of preparations containing St. John's Wort

          8. Participation in other studies involving investigational drug(s) (Phases I-IV) within
             2 weeks before the current study treatment begins

          9. QTc &gt; 480 msec on the screening ECG (using the QTcF formula and/or the QTcB (Bazett)
             formula); history of QT syndrome, Brugada syndrome or known history of QTc
             prolongation, or Torsade de Pointes

         10. High cardiovascular risk, including, but not limited to recent myocardial infarction,
             severe/unstable angina and severe cardiac dysrhythmias in the past 6 months prior to
             enrollment

         11. Patients with advanced symptomatic, visceral spread, that were at risk of
             life-threatening complications in the short term (including patients with massive
             uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and
             over 50% liver involvement)

         12. Diagnosis of any second malignancy within the last 3 years prior to enrollment, except
             for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
             of the cervix

         13. Known, not-irradiated CNS metastases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>iOMEDICO AG</last_name>
    <role>Study Chair</role>
    <affiliation>Freiburg / Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerlinde Bing</last_name>
    <phone>0049- 761- 152420</phone>
    <email>gerlinde.bing@iomedico.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>iOMEDICO AG</last_name>
    <phone>0049- 761- 152420</phone>
    <email>info@iomedico.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baden-Baden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>3 Research Sites</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bottrop</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Bremerhaven</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Dessau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donauwörth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reaearch Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gerlingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Goslar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Güstrow</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>2 Research Sites</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heilbronn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Ilsede</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Langen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leer</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Luneburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Lörrach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mühlhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Mülheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Neumünster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Passau</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Porta Westfalica</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Saarbrucken</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Schorndorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Speyer</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Stade</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Stolberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Traunstein</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Villingen-Schwenningen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Westerstede</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wilhelmshaven</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Würselen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Site</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR+</keyword>
  <keyword>HER2-</keyword>
  <keyword>Locally advanced (inoperable or metastatic) Breast Cancer</keyword>
  <keyword>Palbociclib</keyword>
  <keyword>Aromatase inhibitor or fulvestrant</keyword>
  <keyword>Pre-/perimenopausal receiving LHRH agonist / ovarian ablation</keyword>
  <keyword>Postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

